Roche and Voluntis S.A. introduce CoaguChek® Link, an online resource that helps simplify and streamline the process of managing patients on anticoagulation therapy.
The Web-based application gives patients who self-test their PT/INR (clotting time) a way to report their test results and gives doctors a single, secure site to access data to more effectively monitor and manage their patients on warfarin therapy. It is available to physicians who prescribe a patient self-testing program through CoaguChek Patient Services (CPS), an Independent Diagnostic Testing Facility that provides support services for physicians and their patients. The application is based on the Medpassport platform developed by Voluntis, a health care software company specializing in patient relationship management.
“CoaguChek Link helps doctors and their patients stay connected so they can work together to manage the patient’s anticoagulation therapy more effectively, whether the patient is at home or away,” said Tim Huston, director of marketing, professional diagnostics at Roche Diagnostics Corporation. “It simplifies the process for everyone, facilitates better therapy management, and contributes to the goal of helping improve patient outcomes.”
CoaguChek Link offers healthcare providers a convenient patient management resource, helping to simplify documentation and streamline office workflow so they can focus on patients that require follow-up care. Clinics and physician offices can use the application to quickly enroll patients with CPS, educate them about their therapy, view test results in real time through a password-protected portal, modify recommended test frequency or acceptable ranges for patient test results, and generally access the information needed to monitor and adjust a patient’s anticoagulant therapy from anywhere. If a patient doesn’t report results according to schedule or the results are outside of the range the doctor specifies, the system automatically flags it and the patient’s health care provider and CPS clinical specialists are notified.
Source: Roche
